Combating opiate dependence: a comparison among the available pharmacological options

Bibliography

• VAN DER BURGH C: A review of the drug abuse situation in the world. Proceedings of National Institute on Drug Abuse, US Dept of Health and Human Services, Rockville, MD, USA (1999).
   Google Scholar
• SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION: Summary of findings from 1998 National Household Survey on Drug Abuse (1999).
   Google Scholar
• SLOBODA Z. Drug abuse patterns in the United States. In: Epidenhologic trends in drug abuse (Vol. 2). Proceedings of the International epidemiology Work Group on Drug Abuse (1999):89–107.
   Google Scholar
• ROUNSAVILLE BJ, KOSTEN TR. Treatment for opioid dependence: quality and access. J. Ain. Med. Assoc. (2000) 283(10):1337–1339.
   PubMed Web of Science ®Google Scholar
• NIH CONSENSUS PANEL: Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiateaddiction. J. Ant. Med. Assoc. (1999)280(22):1936–1943.
   Google Scholar
• WARD J, BELL J, MATTICK RP EA: Methadone maintenance therapy for opioid dependence: a guide to appropriate use. CNS Drugs (1996) 6(6):440–449.
   Google Scholar
• KRANTZ MJ, LEWKOWIEZ L, HAYS H, WOODROFFE MA, ROBERTSON AD, MEHLER PS: Torsade de pointes associated with very-high-dose methadone.Ann. Intern. Med. (2002) 137(6):501-504.
   Google Scholar
• MARTELL BA, ARNSTEN JH, RAY B, GOUREVITCH MN: The impact of methadone induction on cardiac conduction in opiate users. Ann. Intern. Med. (2003) 139(2):154–155.
   PubMed Web of Science ®Google Scholar
• DEAMER RL, WILSON DR, CLARK DS, PRICHARD JG: Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). j Addict. Dis. (2001) 20(4):7–14.
   PubMed Web of Science ®Google Scholar
• EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS: EMEA public statement on the recommendation to suspend themarketing authorization for ORLAAM (Levaacetyl methadol) in the European Union (2003).
   Google Scholar
• FDA: ORLAAM. In: Index of safety-related drug labeling change summaries approved by FDA center for drug evaluation and research (CDEP) (2001).
   Google Scholar
• MARGOLIN A, KOSTEN TR: Opioid detoxification and maintenance with blocking agents. In: Comprehensive handbook of drug and alcohol addiction. Miller NS (Ed.) (1991):1127–1147.
   Google Scholar
• SENAY EC, DORUS W, GOLDBERG F: Withdrawal from methadone maintenance. Arch. Gen. Psychiatry (1977) 34:361–367.
   PubMed Web of Science ®Google Scholar
• LOWINSON JH, PAYTE JT, SALSITZ E: Methadone maintenance: In: Substance Abuse, A Comprehensive Textbook (Id edit). Lowinson JH, Ruiz P, Millman RB, Langrod JG (Eds), Williams and Wilkins; Baltimore, MD, USA (1997).
   Google Scholar
• KREEK MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future inmainstream medicine. Ann. NY Acad. Sci.(2000) 909:186–216.
   PubMed Web of Science ®Google Scholar
• MATTICK RP, BREEN C, KIMBER J, DAVOLI M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev (2003) 2:CD002209.
   Google Scholar
• BALL JC, ROSS A: The effectiveness of methadone maintenance treatment. (1991):212–232.
   Google Scholar
• GEARING FR, SCHWEITZER MD: An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am. J. Epidemiol (1974) 100(2):101–112.
   PubMed Web of Science ®Google Scholar
• CONCOOL B, SMITH H, STIMMEL B: Mortality rates of persons entering methadone maintenance: a seven-year study. Am. J. Drug Alcohol Abuse (1979) 6(3):345–353.
   PubMed Web of Science ®Google Scholar
• CAPLEHORN JR, DALTON MS, CLUFF MC, PETRENAS AM: Retention in methadone maintenance and heroin addicts' risk of death. Addiction (1994) 89(2):203–209.
   PubMed Web of Science ®Google Scholar
• GRONBLADH L, OHLUND LS, GUNNE LM: Mortality in heroin addiction: impact of methadone treatment. [see comments]. Acta Psychiatr. Scand. (1990) 82(3):223–227.
   PubMed Web of Science ®Google Scholar
• BARNETT PG: The cost-effectiveness of methadone maintenance as a health care intervention. Addiction (1999) 94(4):479–488.
   PubMed Web of Science ®Google Scholar
• IRIBARNE C, BERTHOU F, CARLHANT D et al.: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab. Dispos. (1998) 26(3):257–260.
   PubMed Web of Science ®Google Scholar
• ALTICE FL, FRIEDLAND GH, COONEY EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS(1999) 13(8):957–962.
   PubMed Web of Science ®Google Scholar
• JUDSON BA, GOLDSTEIN A:Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization. Drug Alcohol Depend. (1979) 4(6):461–466.
   PubMedGoogle Scholar
• LING W, CHARUVASTRA C, KAIM SC, KLETT CJ: Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch. Gen. Psychiatry (1976) 33(6):709–720.
   PubMed Web of Science ®Google Scholar
• JONES HE, STRAIN EC, BIGELOW GE et al.: Induction with levomethadyl acetate: safety and efficacy. Arch. Gen. Psychiatry (1998) 55(8):729–736.
   PubMedGoogle Scholar
• TENNANT FS Jr, PAWS ON RA, PUMPHREY E, SEECOF R: Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). I Subst. Abuse Treatment (1986) 3(3):195–202.
   PubMedGoogle Scholar
• EISSENBERG T, BIGELOW GE, STRAIN EC et al: Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA (1997) 277(24):1945–1951.
   PubMed Web of Science ®Google Scholar
• JUDSON BA, GOLDSTEIN A, INTURRISI CE: Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification. Arch. Gen. Psychiatry (1983) 40(8):834–840.
   PubMedGoogle Scholar
• Opioid drugs in maintenance and detoxification treatment of opiate addiction; Substance Abuse and Mental Health Services Administration, HHS. Final rule. Fed. Regist. (2001) 66(11):4076–4102.
   PubMedGoogle Scholar
• WILKERSON D, MIGAS N, SLAVEN T: Outcome-oriented standards and performance indicators for substance dependency rehabilitation programs. Subst. Use Misuse (2000) 35(12-14):1679–1703.
   PubMed Web of Science ®Google Scholar
• COOPER JR: Including narcotic addiction treatment in an office-based practice. JAMA (1995) 273(20):1619–1620.
   PubMed Web of Science ®Google Scholar
• NOVICK DM, JOSEPH H, SALSITZ EA et al.: Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J. General Intern. Med. (1994) 9(3):127–130.
   PubMed Web of Science ®Google Scholar
• NOVICK DM, PASCARELLI EF, JOSEPH H EA: Methadone maintenance patients in general medical practice. A preliminary report. J. Am. Med. Assoc. (1998) 259:3299–3302.
   Google Scholar
• OBADIA Y, PERRIN V, FERONI I, VLAHOV D, MOATTI JP: Injecting misuse of buprenorphine among French drug users. Addiction (2001) 96(2):267–272.
   PubMed Web of Science ®Google Scholar
• FUDALA PJ, BRIDGE TP, HERBERT S: A multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment.NIDA Res. Monogr: (1998) 179:105.
   Google Scholar
• AMASS L, KAMIEN JB, MIKULICH SK: Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. (2000) 58(1-2):143–152.
   PubMed Web of Science ®Google Scholar
• AMASS L, KAMIEN JB, MIKULICH SK: Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. (2001) 61(2):173–181.
   PubMed Web of Science ®Google Scholar
• KUHLMAN JJ, JR, LEVINE B,JOHNSON RE, FUDALA PJ, CONE EJ: Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction (1998) 93(4):549–559.
   PubMed Web of Science ®Google Scholar
• RANCE MJ, DICKENS JN: The influence of drug-receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine. In: Characteristics and function of opioids. Van Ree JM, Pereniums L (Eds), Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands (1978):65–66.
   Google Scholar
• PETRY NM, BICKEL WK, BADGER GJ: Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction (2001) 96(6):823–834.
   PubMed Web of Science ®Google Scholar
• WALSH SL, PRESTON KL,BIGELOW GE, STITZER ML: Acute administration of buprenorphine in humans: partial agonist and blockade effects. Pharmacol Exp. Ther: (1995) 274(1):361–372.
   PubMed Web of Science ®Google Scholar
• WALSH SL, PRESTON KL,STITZER ML, CONE EJ, BIGELOW GE: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol Ther. (1994) 55(5):569–580.
   PubMed Web of Science ®Google Scholar
• LANGE WR, FUDALA PJ, DAX EM, JOHNSON RE: Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. (1990) 26(1):19–28.
   PubMedGoogle Scholar
• HUESTIS MA, UMBRICHT A, PRESTON KL EAL: Safety of buprenorphine: no clinically relevant cardio-respiratory depression at high IV doses. In: Problems of Drug Dependence. Harris LS (Ed.), NIDA Res. Monogr: (1999) 179:62.
   Google Scholar
• GOWING L, ALI R, WHITE J: Buprenorphine for the management ofopioid withdrawal. Cochrane Database of Syst. Rev (2000) 3:CD002025.
   Google Scholar
• UMBRICHT A, MONTOYA ID, HOOVER DR et al.: Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend (1999) 56(3):181–190.
   PubMed Web of Science ®Google Scholar
• NIGAM A, RAY R, TRIPATHI BM: Buprenorphine in opiate withdrawal: a comparison with clonidine. I Subst. Abuse Treat. (1993) 10:391–394.
   PubMed Web of Science ®Google Scholar
• JANIRI L, MANNELLI P, PERSICO AM, SERRETTI A, TEMPESTA E: Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. (1994) 36(2):139–145.
   PubMedGoogle Scholar
• CHESKIN LJ, FUDALA PJ,JOHNSON RE: A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend (1994) 36(2):115–121.
   PubMed Web of Science ®Google Scholar
• O'CONNOR PG, CARROLL KM, SHI JM, SCHOTTENFELD RS, KOSTEN TR, ROUNSAVILLE BJ: Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann. Intern. Med. (1997) 127(7):526–530.
   PubMed Web of Science ®Google Scholar
• BICKEL WK, AMASS L: Buprenorphine treatment of opioid dependence: a review. Exp. Gin. Psychopharmacol (1995) 3(4):477–489.
   Web of Science ®Google Scholar
• JOHNSON RE, STRAIN EC, AMASS L: Buprenorphine: how to use it right.Drug Alcohol Depend (2003)70(2 Suppl.):S59–S77.
   Google Scholar
• LINTZERIS N, BELL J, BAMMER G, JOLLEY DJ, RUSHWORTH L: A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction (2002) 97(11):1395–1404.
   PubMed Web of Science ®Google Scholar
• FINGERHOOD MI, THOMPSON MR, JASINSKI DR: A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst. Abus. (2001) 22(3):193–199.
   PubMedGoogle Scholar
• BICKEL WK, AMASS L, HIGGINS ST, BADGER GJ, ESCH RA: Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Consult. Gin. Psychology (1997) 65(5):803–810.
   PubMed Web of Science ®Google Scholar
• AMASS L, BICKEL WK, HIGGINS ST, HUGHES JR: A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. I Addict. Dis. (1994) 13(3):33–45.
   PubMed Web of Science ®Google Scholar
• LING W, CHARUVASTRA C, COLLINS JF et al.: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction (1998) 93(4):475–486.
   PubMed Web of Science ®Google Scholar
• RESNICK RB, GALANTER M,PYCHA C, COHEN A, GRANDISON P, FLOOD N: Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull. (1992) 28(1):109–113.
   PubMedGoogle Scholar
• RESNICK RB, RESNICK E, GALANTER M: Buprenorphine responders: a diagnostic subgroup of heroin addicts? Progress M Neuro-Psychopharmacol Biol. Psychiatry (1991) 15(4):531–538.
   Google Scholar
• KOSTEN TR, MORGAN C,KLEBER HD: Treatment of heroin addicts using buprenorphine. Am. I Drug Alcohol Abuse (1991) 17(2):119–128.
   PubMed Web of Science ®Google Scholar
• FIELLIN DA: Treatment of heroin dependence with buprenorphine in primary care. Am. Drug Alcohol Abuse 28(2):241.
   Google Scholar
• JOHNSON RE, CHUTUAPE MA, STRAIN EC, WALSH SL, STITZER ML, BIGELOW GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. [see comments]. N Engl. Med. (2000) 343(18):1290–1297.
   PubMed Web of Science ®Google Scholar
• VIGNAU J, BRUNELLE E: Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Ear. Addiction Res. (1998)4\(Suppl. 1):24–28.
   Google Scholar
• BARRAU K, THIRION X, MICALLEF J, CHUNIAUD-LOUCHE C,BELLEMIN B, SAN MARCO JL: Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction (2001) 96(10):1441.
   Google Scholar
• THIRION X, MICALLEF J, BARRAU K et al.: Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend. (2001) 61(3):281–285.
   PubMedGoogle Scholar
• TRACQUI A, KINTZ P, LUDES B: Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal Toxicol (1998) 22:430–433.
   PubMed Web of Science ®Google Scholar
• KINTZ P: Deaths involvingbuprenorphine: a compendium of French cases. Forensic Sci. mt. (2001) 121:65–69.
   PubMed Web of Science ®Google Scholar
• KINTZ P: A new series of 13 buprenorphine-related deaths. Clin. Biochem. (2002) 35(7):513–516.
   PubMed Web of Science ®Google Scholar
• STOLLER KB, BIGELOW GE, WALSH SL, STRAIN EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacologia (2001) 154(3):230–242.
   PubMed Web of Science ®Google Scholar
• GOLD MS, POTTASH AL: Endorphins, locus coerulus, clonidine and lofexidine: a mechanism for opiate withdrawal and new nonopiate treatments. Adv. Alcohol Subst. Abuse (1981) 1(1):33–52.
   Google Scholar
• WASHTON AM, RESNICK RB: Recent advances in opiate detoxification: clonidine and lofexidine. NIDA Res. Monogr. (1983) 43:44–50.
   PubMedGoogle Scholar
• BEARN J, GOSSOP M, STRANG J: Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend (1998) 50(3):227–232.
   PubMed Web of Science ®Google Scholar
• KAHN A, MUMFORD JP, ROGERS GA, BECKFORD H: Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. (1997) 44(1):57–61.
   PubMedGoogle Scholar
• GOLD MS, REDMOND DE, JR, KLEBER HD: Clonidine blocks acute opiate-withdrawal symptoms.Lancet (1978) 2(8090):599–602.
   Google Scholar
• WASHTON AM, RESNICK RB: Clonidine for opiate detoxification: outpatient clinical trials. Am. I Psychiatry (1980) 137(9):1121–1122.
   PubMed Web of Science ®Google Scholar
• CHARNEY DS, STERNBERG DE, KLEBER HD, HENINGER GR, REDMOND DE Jr: The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch. Gen. Psychiatry (1981) 38(11):1273–1277.
   Google Scholar
• KLEBER HD, RIORDAN CE, ROUNSAVILLE B et al.: Clonidine in outpatient detoxification from methadone maintenance. Arch. Gen. Psychiatry (1985) 42(4):391–394.ao.ASIN KE, WIRTSHAFTER D: Clonidineproduces a conditioned place preference in rats. Psychopharmacology (1985) 85(3):383–385.
   Google Scholar
• DAVIS WM, SMITH SG: Catecholaminergic mechanisms of reinforcement: direct assessment by drug-self-administration. Life Sci. (1977) 20(3):483–492.
   PubMedGoogle Scholar
• LAUZON P: Two cases of clonidine abuse/dependence in methadone-maintained patients. I Subst. Abuse Treatment (1992) 9(2):125–127.
   PubMedGoogle Scholar
• LIN SK, STRANG J, SU LW, TSAI CJ, HU WH: Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. (1997) 48(2):127–133.
   PubMedGoogle Scholar
• CARNWATH T, HARDMAN J: Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.Drug Alcohol Depend. (1998)50(3):251–254.
   PubMedGoogle Scholar
• GERRA G, ZAIMOVIC A, GIUSTI F et al.: Lofexidine versus clonidine in rapid opiate detoxification. J Subst. Abuse Treatment (2001) 21(1):11–17.
   PubMedGoogle Scholar
• KLEBER HD, TOPAZIAN M,GASPARI J, RIORDAN CE, KOSTEN T: Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am. J. Drug Alcohol Abuse (1987) 13(1-2):1–17.
   PubMed Web of Science ®Google Scholar
• GOWING L, ALI R, WHITE J: Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. [Review] [4 refs]. Cochrane Database of Syst. Rev (2000) 2:CD002021.
   Google Scholar
• O'CONNOR PG, WAUGH ME, CARROLL KM, ROUNSAVILLE BJ, DIAGKOGIANNIS IA, SCHOTTENFELD RS: Primary care-based ambulatory opioid detoxification: the results of a clinical trial. I Gen. Intern. Med. (1995) 10(5):255–260.
   PubMed Web of Science ®Google Scholar
• GERRA G, MARCATO A,CACCAVARI R et al: Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J. Subst. Abuse Treatment (1995) 12(1):35–41.
   PubMed Web of Science ®Google Scholar
• GERRA G, ZAIMOVIC A, RUSTICHELLI P et al.: Rapid opiate detwdcation in outpatient treatment: relationship with naltrexone compliance., " Subst. Abuse Treatment (2000) 18(2):185–191.
   Google Scholar
• VINING E, KOSTEN TR, KLEBER HD: Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br. J. Addiction (1988) 83(5):567–575.
   PubMedGoogle Scholar
• LOIMER N, SCHMID R, PRESSLICH 0, LENZ K: Naloxone treatment for opiate withdrawal syndrome. Br. J. Psychiatry (1988) 153:851–852.
   PubMedGoogle Scholar
• LOIMER N, SCHMID R, LENZ K, PRESSLICH 0, GRUNBERGER J: Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br. J. Psychiatry (1990) 157:748–752.
   PubMed Web of Science ®Google Scholar
• BADENOCH J: A death following ultra-rapid opiate detoxification: the General Medical Council adjudicates on a commercialized detoxification. Addiction (2002) 97(5):475–477.
   PubMedGoogle Scholar
• HAMILTON RJ, OLMEDO RE, SHAH S et al.: Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad. Emerg. Med. (2002) 9(1):63–68.
   PubMed Web of Science ®Google Scholar
• GOLD CG, CULLEN DJ, GONZALES S, HOUTMEYERS D, DWYER MJ: Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology (1999) 91(6):1639–1647.
   PubMed Web of Science ®Google Scholar
• O'CONNOR PG, KOSTEN TR: Rapid and ultrarapid opioid detoxification techniques. [see comments]. JAMA (1998) 279(3):229–234.
   PubMed Web of Science ®Google Scholar
• SCHERBAUM N, KLEIN S, KAUBE H, KIENBAUM P, PETERS J, GASTPAR M: Alternative strategies of opiate detoxification: evaluation of theso-called ultra-rapid detoxification. Pharmacopsychiatty (1998) 31(6):205–209.
   PubMed Web of Science ®Google Scholar
• O'CONNOR PG, KOSTEN TR, STEIN SM: Management of opioid intoxication and withdrawal. In: Principles of Addition Medicine (.7d eda. Graham AW, Schultz TK, Mayo-Smith MF, Ries RK (Eds), American Society of Addiction Medicine, Washington, DC, USA (2003):651–667.
   Google Scholar
• RABINOWITZ J, COHEN H,TARRASCH R, KOTLER M: Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend. (1997) 47(2):77–86.
   PubMed Web of Science ®Google Scholar
• O'CONNOR PG, FIELLIN DA: Pharmacologic treatment of heroin-dependent patients. Ann. Intern. Med. (2000) 133(1):40–54.
   PubMed Web of Science ®Google Scholar
• CUCCHIA AT, MONNAT M, SPAGNOLI J, FERRERO F, BERTSCHY G: Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend. (1998) 52(3):243–250.
   PubMed Web of Science ®Google Scholar
• SAN L, PUIG M, BULBENA A, FARRE M: High risk of ultrashortnoninvasive opiate detoxification.Am. J. Psychiatry (1995) 152(6):956.
   Google Scholar
• PFAB R, HIRTL C, ZILKER T: Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure., " Toxicol Clin. Toxicol (1999) 37(1):43–50.
   Google Scholar
• ZIELBAUER P: State knew of risky heroin treatment before patient deaths. (1999):41.
   Google Scholar
• STRANG J, BEARN J, GOSSOP M: Opiate detoxification under anaesthesia. [see comments]. Br. Med. J. (1997) 315(7118):1249–1250.
   PubMedGoogle Scholar
• ALBANESE AP, GEVIRTZ C, OPPENHEIM B, FIELD JM, ABELS I, EUSTACE JC: Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J. Addict. Dis. (2000) 19(2):11–28.
   PubMed Web of Science ®Google Scholar
• HENSEL M, KOX WJ: Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesia Scand. (2000) 44(3):326–333.
   PubMed Web of Science ®Google Scholar
• LAWENTAL E: Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program - a retrospective follow-up study.Subst. Abuse (2000) 11(2):173–181.
   Google Scholar
• MARRAZZI MA, WROBLEWSKI JM, KINZIE J, LUBY ED: High-dose naltrexone and liver function safety. Am. Addict. (1997) 6(1):21–29.
   PubMedGoogle Scholar
• KIRCHMAYER U, DAVOLI M, VERSTER A: Naltrexone maintenance treatment for opioid dependence. [review]. Cochrane Database of Syst. Rev (2001) 2(CD001333).
   Google Scholar
• SHUFMAN EN, PORAT S, WITZTUM E, GANDACU D, BAR-HAMBURGER R, GINATH Y: The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol. Psychiatry (1994) 35(12):935–945.
   PubMed Web of Science ®Google Scholar
• HOLLISTER LE: Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the national research council committee on clinical evaluation of narcotic antagonists. Arch. Gen. Psychiatry (1978) 35(3):335–340.
   Google Scholar
• CURREN S, SAVAGE C: Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of\administration. NIDA Res. Monogr. (1976) 9:67–69.
   Google Scholar
• SAN L, POMAROL G, PERT JM, OLLE JM, CAMI J: Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br. Addiction (1991) 86(8):983–990.
   Google Scholar
• LERNER A, SIGAL M, BACALU A, SHIFF R, BURGANSKI I, GELKOPF M: A naltrexone double blind placebo controlled study in Israel. Israel J. Psychiatry Related Sci. (1992) 29(1):36–43.
   PubMedGoogle Scholar
• HULSE G, BASSO MR: Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug Alcohol Rev (1999) 18(3):263–269.
   Google Scholar
• CHIANG CN, HOLLISTER LE, GILLESPIE HK, FOLTZ RL: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. (1985) 16(1):1–8.
   PubMed Web of Science ®Google Scholar
• COMER SD, COLLINS ED, KLEBER HD, NUWAYSER ES, KERRIGAN JH, FISCHMAN MW: Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Ber) (2002) 159(4):351–360.
   PubMed Web of Science ®Google Scholar
• MODESTO-LOWE V, VAN KIRK J: Clinical uses of naltrexone: a review of the evidence. Exp. Clin. Psychopharmacol (2002) 10(3):213–227.
   PubMed Web of Science ®Google Scholar
• CARRENO J, ALVAREZ C,NARCISO GS, BASCARAN M, DIAZ M, BOBES J: Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment ofopioid dependence. Addict Biol. (2003) 8(4):429–438.
   PubMed Web of Science ®Google Scholar
• KOSTEN TR, ROUNSAVILLE BJ, KLEBER HD: Relationship of depression to psychosocial stressors in heroin addicts. Nerv. Ment.Dis (1983) 171(2):97–104.
   PubMedGoogle Scholar
• KOSTEN TR, ROUNSAVILLE BJ, KLEBER HD: A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch. Gen. Psychiatry (1987) 44(3):281–284.
   Google Scholar
• SINHA R, FUSE T, AUBIN LR, O'MALLEY SS: Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) (2000) 152(2):140–148.
   PubMed Web of Science ®Google Scholar
• SINHA R, CATAPANO D, O'MALLEY S: Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology (Berl) (1999) 142(4):343–351.
   PubMed Web of Science ®Google Scholar
• SHAHAM Y, HIGHFIELD D, DELFS J, LEUNG S, STEWART J: Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. Eur.J. Neurosci. (2000) 12(1):292–302.
   PubMedGoogle Scholar
• SHAHAM Y, STEWART J: Stress reinstates heroin-seeking in drug-free animals: an effect mimicking heroin, not withdrawal. Psychopharmacology (Berl) (1995) 119(3):334–341.
   PubMed Web of Science ®Google Scholar
• SINHA R, HOLTZMAN K, HOGAN I et al.: Lofexidine: enhancing naltrexone treatment to prevent stress related opiate relapse. Proceding of Proceedings College on Problems of Drug Dependence. Bal Harbour, Florida, USA (2003).
   Google Scholar
• FIELLIN DA: Office-based treatment for opioid dependence: reaching new patient populations. Am. J. Psychiatry158(8):1204.
   Google Scholar
• FUDALA PJ, BRIDGE TP, HERBERT S et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl. I Med. (2003) 349(10):949–958.
   PubMed Web of Science ®Google Scholar
• CARRIERI MP, REY D, LOUNDOU A, LEPEU G, SOBEL A, OBADIA Y: Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend. (2003) 72(1):13–21.
   PubMed Web of Science ®Google Scholar
• GUEYE PN, MEGARBANE B, BORRON SW et al.: Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction (2002) 97(10):1295–1304.
   PubMed Web of Science ®Google Scholar
• JONES HE, JOHNSON RE,FUDALA PJ, HENNINGFIELD JE, HEISHMAN SJ: Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend. (2000) 60(1):29–37.
   PubMedGoogle Scholar